** Shares of medical device maker RenovoRx RNXT.O rise 5.6% to $1.02 premarket

** Co says it raised about $10 million in an oversubscribed private stock offering led by institutional investors, with participation from management.

** Adds proceeds from the sale will support the commercial rollout of RenovoCath, an FDA-cleared device that delivers drugs directly to cancer tumors to limit side effects

** Says funds will also back its late-stage study of an experimental combination therapy for pancreatic cancer, which is hard to treat

** Co aims to reach operational breakeven and complete trial enrollment by mid-2026, with results expected in 2027

** Shares up ~15% YTD vs. a ~35% fall in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))